AstraZeneca Pharma India Limited — Important, 04-04-2025: General Updates

AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organization to import and distribute Osimertinib Tablets (40 mg & 80 mg), expanding its indications. This new approval enables the use of Osimertinib in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) featuring specific EGFR mutations.

The marketing of these tablets in India, pending any further statutory approvals, signifies a strategic expansion in AstraZeneca's oncology portfolio, potentially enhancing its market position and addressing a critical treatment need. This development could foster a positive outlook among investors, as it may drive revenue growth in a key therapeutic area.